Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage to Start Phase III Trials of Bcl-2 Inhibitor for MDS

publication date: Aug 13, 2024

Suzhou Ascentage Pharma has been cleared to start China Phase III trials of lisaftoclax (APG-2575) as a first-line treatment of newly-diagnosed patients with higher-risk myelodysplastic syndrome (MDS). Lisaftoclax will be administered in combination with azacitidine (AZA). Lisaftoclax is a novel, oral Bcl-2 selective inhibitor that is designed to block the antiapoptotic protein Bcl-2, restoring the normal apoptosis process in cancer cells. The approval is the fourth Phase III trial for the candidate in China. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here